Dear SOC Medicare Participants,

Please be advised that this program is not part of the SOC Medicare OptumRx Plan.

We are sharing important information regarding an upcoming program administered by Medicare that may help eligible members obtain access to GLP-1 weight-loss medications at a reduced cost.

The Medicare GLP-1 Bridge Program, scheduled to begin July 1, 2026, and continue through December 31, 2027, is a program administered by Medicare and is separate from the SOC EGWP Medicare Part D Plan.

This Medicare initiative may allow eligible Medicare Part D members access to certain GLP-1 medications for weight management at a fixed monthly copay of $50.

Eligibility Notice (SOC Members):

To participate in the Medicare GLP-1 Bridge Program, you must be enrolled in a Medicare Part D plan which includes the SOC EGWP Medicare Part D plan. The SOC is currently the only NYPD Union offering a Medicare Part D Plan which makes our members eligible for this program.

Program Overview:

• Monthly copay: $50
• Includes select GLP-1 medications (such as Wegovy® and Zepbound® KwikPen® when prescribed for weight management).
• Program is separate from the standard Medicare Part D benefit structure.
• Part D deductible and out-of-pocket accumulation do not apply.
• Extra Help (Low-Income Subsidy) cost-sharing does not apply.
• Prior authorization is required through your healthcare provider.

What should you do?

If you are currently taking a GLP-1 medication—or are considering starting one for weight loss - please consult your physician to determine whether this program may be appropriate for your individual health needs.

To access GLP-1 medications via the Medicare GLP-1 Bridge, an eligible beneficiary must have a medical provider submit a prior authorization request and a prescription for an eligible GLP-1 drug to Medicare for approval.Prior authorization requests will be accepted electronically or by fax using the Medicare GLP-1 Bridge prior authorization form on the Medicare website. CMS strongly encourages providers to submit prior authorization electronically.

Important note:

This program is intended for use in the treatment of obesity/weight management. Individuals using GLP-1 medications for diabetes management are not included in the weight-management benefit criteria. If you have diabetes, please consult your physician to discuss possible options.

Inquiries regarding this program should not be directed to the SOC or OptumRX. For further information and guidance you can contact Medicare at 1-800-MEDICARE or visit Medicare GLP-1 Bridge | CMS.